What are the percentages of positivity for acetylcholine receptor (AChR) antibodies, muscle-specific kinase (MuSK) antibodies, and other antibodies in patients suspected of having myasthenia gravis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 24, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Antibody Positivity Rates in Myasthenia Gravis

In patients suspected of having myasthenia gravis, approximately 80% with generalized disease test positive for acetylcholine receptor (AChR) antibodies, while only 50% with purely ocular disease are AChR-positive; among those who are AChR-negative, approximately one-third (33%) will be positive for muscle-specific kinase (MuSK) antibodies. 1

AChR Antibody Positivity

  • AChR antibodies are present in approximately 80% of patients with generalized myasthenia gravis, making this the most common antibody detected 1, 2
  • In purely ocular myasthenia gravis, AChR antibody sensitivity drops significantly to only 50% 1, 2
  • A recent 2025 meta-analysis of 44 studies (n=4,937 patients with ocular MG) confirmed 59% pooled positivity for anti-AChR antibodies (95% CI: 52%-66%) 3
  • AChR antibody positivity carries important prognostic implications: patients with positive AChR antibodies have 1.82 times greater risk of progressing from ocular to generalized myasthenia gravis (95% CI: 1.15-2.88) 3
  • Thymoma prevalence is 35% (95% CI: 3%-90%) in AChR-positive ocular myasthenia patients, underscoring the critical importance of detecting these antibodies 3

MuSK Antibody Positivity

  • Among AChR-negative patients, approximately one-third (33%) will test positive for anti-MuSK antibodies 1, 2
  • In the general myasthenia gravis population, MuSK antibodies are detected in approximately 6% of all patients 4
  • In purely ocular myasthenia gravis, MuSK antibody positivity is only 5% (95% CI: 2%-9%) based on pooled analysis of 34 studies (n=3,380 patients) 3
  • A landmark 2001 study demonstrated that 70% of AChR-antibody-seronegative MG patients have MuSK antibodies 5

Other Antibodies and Seronegative Disease

  • Approximately 10% of myasthenia gravis patients remain seronegative by conventional AChR and MuSK testing 4
  • Using more sensitive detection methods in previously seronegative patients reveals: 25% have AChR antibodies, 4% have MuSK antibodies, 7% have LRP4 antibodies, and 6% have titin antibodies when tested with highly sensitive assays 6
  • In total, 37% of conventionally seronegative MG patients test positive for at least one antibody when comprehensive testing with sensitive methods is performed 6
  • LRP4 (low-density lipoprotein receptor-related protein 4) antibodies represent a third autoantigen in myasthenia gravis, though less commonly detected 4

Double-Positive Antibodies

  • Double seropositivity for both AChR and MuSK antibodies is extremely rare, occurring in only 0.1% of patients (4 out of 5,180 patients across 62 studies) 3
  • Patients with coexistence of multiple antibodies tend to have more severe disease compared to single-antibody or seronegative patients 6

Clinical Testing Algorithm

  • Always test AChR antibodies first as the initial diagnostic test, given the 80% positivity rate in generalized disease 1, 2
  • Test MuSK antibodies only when AChR antibodies return negative, as this sequential approach is more cost-effective given MuSK's lower prevalence and higher testing cost 1, 2, 3
  • Consider anti-striated muscle antibodies in the initial workup, particularly given the association with thymoma 1
  • In patients remaining seronegative after conventional testing, consider referral for highly sensitive radioimmunoassays or cell-based assays that can detect antibodies missed by routine methods 6

References

Guideline

Myasthenia Gravis Diagnostic and Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Laboratory Testing for Myasthenia Gravis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

The Diagnostic Yield of Antiacetylcholine Receptor Antibodies Versus Antimuscle Kinase Antibodies in Ocular Myasthenia Gravis: A Meta-Analysis.

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society, 2025

Related Questions

What blood tests are associated with diagnosing and managing myasthenia gravis?
Are the autoantibodies released in myasthenia gravis (MG) stimulatory or inhibitory at the neuromuscular junction?
Can Acetylcholine Receptor (ACHR) antibodies greater than 0.55 be positive for myasthenia gravis without typical symptoms?
Can Myasthenia Gravis (MG) be ruled out by checking for antibodies against the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK)?
What is the pathophysiology of a disease characterized by fluctuating muscle weakness, diplopia, dysphagia, ptosis, and proximal muscle weakness due to antibodies to the acetylcholine (ACh) receptor at the neuromuscular junction?
What is the treatment for acute disseminated encephalitis (ADEM) in a patient of any age, possibly following a viral infection or vaccination?
What treatment options are available for a patient with a history of overstraining, resulting in a fissure and subsequent surgeries, now experiencing erectile dysfunction and decreased libido?
What is the recommended dosage and usage of zopiclona (non-benzodiazepine hypnotic agent) for an adult patient with sleep disturbances, possibly related to anxiety or neuropathic pain?
Is Enfortumab Vedotin (Monoclonal Antibody Conjugate) dialyzable in patients with impaired renal function?
What is the best approach to manage edema in a patient with chronic kidney disease (CKD) and impaired renal function?
What is the appropriate treatment for a patient with an infected deep partial-thickness burn?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.